Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 4/20 | 0.50 |
| ▸ | CDK2 | P24941 | 3/20 | 0.48 |
| ▸ | GSK3B | P49841 | 3/20 | 0.48 |
| ▸ | MMP13 | P45452 | 3/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13734537 | 0.83 | LOX (0.54) | WDR5CDK2GSK3BMMP13TRPA1 | |
| SCHEMBL21711620 | 0.83 | WDR5 (0.47) | WDR5NTRK1ADORA2APOLB | |
| SCHEMBL21711932 | 0.82 | WDR5 (0.45) | WDR5MMP13MAPTPOLB | |
| SCHEMBL21712006 | 0.80 | WDR5 (0.75) | WDR5NTRK1EPHX2 | |
| SCHEMBL21711806 | 0.78 | WDR5 (0.44) | WDR5MMP13 | |
| SCHEMBL21711705 | 0.78 | WDR5 (0.50) | WDR5MMP13 | |
| SCHEMBL21712079 | 0.78 | WDR5 (0.43) | WDR5MMP13 | |
| SCHEMBL21712097 | 0.78 | TSHR (0.52) | WDR5EPHX2 | |
| SCHEMBL21712086 | 0.76 | HPGD (0.43) | WDR5MMP13POLB | |
| SCHEMBL21712106 | 0.75 | WDR5 (0.51) | WDR5MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807959-B2 | WDR5-MLL1 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200055824-A1 | WDR5-MLL1 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807959-B2 | WDR5-MLL1 inhibitors and modulators | WDR5, WDR1, WDR3 | WDR5 1/4885CDK2 191/4885GSK3B 2395/4885 |
| US-20200055824-A1 | WDR5-MLL1 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | WDR5 1/4885CDK2 191/4885GSK3B 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.